Generalized Anxiety Disorder Clinical Trial
Official title:
Cognitive-Behavioural Treatment for Generalized Anxiety Disorder: Impact of Cognitive Processing on Short- and Long-Term Outcomes
Generalized anxiety disorder (GAD) is a condition characterized by chronic and excessive worry and anxiety. Over the past 15 years, the investigators have developed a cognitive-behavioural treatment that leads to the remission of GAD in approximately 60% to 75% of affected individuals. Although these numbers are encouraging, there remain a considerable proportion of patients who do not fully benefit from treatment. With the goal of improving treatment efficacy, the investigators have recently carried out a series of related studies on the way individuals with GAD and high worriers process uncertain or ambiguous information from their environment. The findings show that these individuals display biases in attention for, and appraisal of, uncertain or ambiguous information. Specifically, individuals with GAD and high worriers preferentially allocate their attention to uncertainty-related stimuli and appraise ambiguous information in a threatening manner. In this study, the investigators examine the impact of these information processing biases, measured at intake, on the efficacy of cognitive-behavioural treatment for GAD. The investigators also examine the impact of residual information processing biases, measured at posttreatment, on the maintenance of treatment gains over 18 months following treatment. The main hypotheses are (1) that high levels of pretreatment biases will predict poorer outcomes immediately following therapy, and (2) that high levels of posttreatment biases will predict relapse during the 18 months following therapy. If, as expected, information processing biases predict poor short- and long-term treatment outcomes for individuals with GAD, the investigators will expand the treatment to integrate strategies that directly target these biases in order to increase its efficacy.
Background: The investigators have developed a cognitive model of generalized anxiety
disorder (GAD) that has intolerance of uncertainty as its central component. Based on this
model, they have devised a cognitive-behavioural treatment (CBT) for GAD that helps affected
individuals recognize, accept, and deal with the uncertainty of everyday life. Although the
treatment leads to positive outcomes in most patients, a significant minority of treated
individuals do not attain full remission. One potential avenue for improving the treatment
of GAD is to identify disorder-specific modes of cognitive processing (or information
processing) and to directly target these modes of processing in therapy. Accordingly, the
investigators have carried out a series of related studies examining the relationship
between cognitive processing and GAD. The findings from these studies show that individuals
who have clinical or subclinical GAD (1) preferentially allocate their attention to
uncertainty-related stimuli, and (2) make threatening appraisals of ambiguous information.
Further, the data show that the tendency to make threatening appraisals of ambiguous
information mediates the relationship between intolerance of uncertainty and the symptoms of
GAD. This latter finding is consistent with cognitive theory, which asserts that information
processing mediates the influence of cognitive vulnerability on the expression of symptoms
of emotional disorders. This study aims to extend this line of research by investigating the
impact of these cognitive processing biases on treatment outcome for patients with GAD.
Goals and hypotheses: The main goal of the study is to examine the impact of biases in
cognitive processing on short- and long-term outcomes of cognitive-behavioural therapy for
individuals with GAD. The study's main hypotheses are that: (1) preferential allocation of
attention to uncertainty-related stimuli, assessed at pretreatment, will predict poorer
response to treatment; (2) the tendency to appraise ambiguous information in a threatening
manner, assessed at pretreatment, will predict poorer response to treatment; (3)
preferential allocation of attention to uncertainty-related stimuli, assessed at
posttreatment, will predict relapse during follow-up; and (4) the tendency to appraise
ambiguous information in a threatening manner, assessed at posttreatment, will predict
relapse during follow-up.
Method: The final sample consists of 80 adult patients with a principal diagnosis of GAD,
recruited from the Anxiety Disorders Clinic of Sacré-Cœur Hospital of Montreal. Participants
are assessed at 9 measurement times: pretreatment, midtreatment, posttreatment, and 3-, 6-,
9-, 12-, 15- and 18-month follow-up. Assessments include the Anxiety Disorders Interview
Schedule for DSM-IV, a cognitive processing task (Ambiguous/Unambiguous Situations Diary),
and a battery of standardized self-report measures. Treatment consists of an empirically
supported CBT protocol for GAD, which is administered over 16 weekly sessions using a
session-by-session treatment manual developed in earlier studies. Growth curve analysis with
multilevel modeling will be the main analytic strategy used to determine the relationships
between cognitive processing and change in a range of outcome variables while controlling
for relevant clinical and sociodemographic variables.
Implications: The study has important theoretical and clinical implications. In terms of
theory, it begins to bridge the gap between the considerable knowledge of the role of
cognitive processing in anxiety and the lack of knowledge of the impact of cognitive
processing on treatment outcomes. Surprisingly, although the role of cognitive processing in
anxiety has been intensely studied, the impact of cognitive processing on GAD psychotherapy
outcomes has never been examined. The proposed study also informs clinical practice as to
the importance of (1) systematically assessing cognitive processing, and (2) integrating
treatment interventions that specifically target biased cognitive processing into current
GAD treatment protocols.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT03420456 -
Transcranial Pulse Near-Infrared Light in Generalized Anxiety Disorder: a Placebo-Controlled Study
|
N/A | |
Active, not recruiting |
NCT05530642 -
An Augmented Training Program for Preventing Post-Traumatic Stress Injuries Among Diverse Public Safety Personnel
|
N/A | |
Withdrawn |
NCT02382224 -
Worry Exposure for Generalized Anxiety Disorder
|
N/A | |
Completed |
NCT02306356 -
Internet-delivered Treatment for Children With Anxiety Disorders in a Rural Area; an Open Trial in a Clinical Setting
|
N/A | |
Completed |
NCT02256566 -
Cognitive Training for Mood and Anxiety Disorders
|
N/A | |
Completed |
NCT01958788 -
Testing Beliefs About Uncertainty in the Treatment of Generalized Anxiety Disorder
|
N/A | |
Completed |
NCT01681329 -
Cognitive-Behavioral Treatment and Interpretation Modification Training for Adults With Generalized Anxiety Disorder
|
N/A | |
Completed |
NCT01337713 -
Efficacy of Massage Therapy in the Treatment of Generalized Anxiety Disorder (GAD)
|
N/A | |
Completed |
NCT01201967 -
A Collaborative Care Program to Improve Treatment of Depression and Anxiety Disorders in Cardiac Patients
|
Phase 4 | |
Completed |
NCT01342120 -
PHARMO Institute Seroquel Safety Study
|
N/A | |
Completed |
NCT01971203 -
Efficacy of Extended-release Quetiapine (Seroquel XR) as Adjunctive Therapy to Cognitive Behavioral Therapy in the Treat
|
N/A | |
Completed |
NCT01203293 -
Cognitive Behavioral Therapy (CBT) for Latinos With Generalized Anxiety Disorder in the General Medical Sector
|
Phase 1 | |
Completed |
NCT00961298 -
An Open Label Trial of Duloxetine in the Treatment of Irritable Bowel Syndrome and Comorbid Generalized Anxiety Disorder
|
Phase 4 | |
Completed |
NCT00711737 -
Study of the Changes in Metabolic Parameters in Patients Treated With Escitalopram for Six Months
|
N/A | |
Terminated |
NCT01244711 -
Open-Label Pilot Study to Examine the Value of Substituting Quetiapine for Benzodiazepines
|
Phase 4 | |
Completed |
NCT00744627 -
Efficacy and Safety of Vortioxetine (Lu AA21004) for Treatment of Generalized Anxiety Disorder in Adults.
|
Phase 3 | |
Completed |
NCT00515242 -
Therapeutic Massage for Generalized Anxiety Disorder
|
Phase 1/Phase 2 | |
Completed |
NCT00525226 -
Evaluating the Effects of Stress in Pregnancy
|
N/A | |
Completed |
NCT00537615 -
An Open-label Study to Investigate the Absorption, Metabolism and Excretion of Radiolabeled PD 0332334 in Six Healthy Male Volunteers
|
Phase 1 | |
Completed |
NCT00368745 -
Efficacy and Safety of Pregabalin vs Placebo for Generalized Anxiety Disorder (GAD) Symptoms in Subjects Discontinuing Benzodiazepine Treatment and Remaining 6 Weeks on Study Medication, Free From Benzodiazepine Use.
|
Phase 3 |